Ultrasound and immune-boosting drugs may help fight aggressive breast cancer
NCT ID NCT07394387
First seen Feb 06, 2026 · Last updated May 25, 2026 · Updated 17 times
Summary
This study tests whether using focused ultrasound (HIFU) to destroy tumors, with or without an immune-boosting drug (PD-1 inhibitor), before standard chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer. About 58 participants will receive one of two treatment sequences. The main goal is to see if the cancer disappears completely after the full treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.